BlueSky Immunotherapies Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Angel
- Latest Deal Amount
-
$2.05M
- Investors
-
4
BlueSky Immunotherapies General Information
Description
Developer of virotherapy designed for cancer and infectious diseases. The company's technology offers interferon-inducing viral vectors that can activate antiviral and antitumoural responses and focus on properties for developing next-generation immunotherapies, enabling physicians to treat cancer and similar diseases.
Contact Information
Website
www.blueskyvaccines.comCorporate Office
- Mariahilfer Straße 101/1/21
- Vienna, 1060
- Austria
Corporate Office
- Mariahilfer Straße 101/1/21
- Vienna, 1060
- Austria
BlueSky Immunotherapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Angel (individual) | 01-Feb-2019 | $2.05M | Completed | Clinical Trials - General | ||
| 3. Grant | Completed | Startup | ||||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Capitalization | 01-Jan-2013 | Completed | Startup |
BlueSky Immunotherapies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BlueSky Immunotherapies Patents
BlueSky Immunotherapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4251200-A1 | Novel replication deficient influenza a virus inducing high levels of type i interferon | Active | 30-Nov-2020 | ||
| EP-4251200-C0 | Novel replication deficient influenza a virus inducing high levels of type i interferon | Active | 30-Nov-2020 | ||
| US-20240108713-A1 | Novel replication deficient influenza a virus inducing high levels of type i interferon | Pending | 30-Nov-2020 | ||
| EP-4251200-B1 | Novel replication deficient influenza a virus inducing high levels of type i interferon | Active | 30-Nov-2020 | ||
| ES-3005234-T3 | Novel replication deficient influenza a virus inducing high levels of type i interferon | Active | 30-Nov-2020 | A61K39/145 |
BlueSky Immunotherapies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BlueSky Immunotherapies Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Forschungsförderungsgesellschaft | Government | Minority | ||
| INiTS Universitäres Gründerservice | Accelerator/Incubator | Minority | ||
| The Austrian Research Promotion Agency | Government | |||
| Vienna Business Agency | Government |
BlueSky Immunotherapies FAQs
-
When was BlueSky Immunotherapies founded?
BlueSky Immunotherapies was founded in 2013.
-
Where is BlueSky Immunotherapies headquartered?
BlueSky Immunotherapies is headquartered in Vienna, Austria.
-
What is the size of BlueSky Immunotherapies?
BlueSky Immunotherapies has 4 total employees.
-
What industry is BlueSky Immunotherapies in?
BlueSky Immunotherapies’s primary industry is Drug Discovery.
-
Is BlueSky Immunotherapies a private or public company?
BlueSky Immunotherapies is a Private company.
-
What is BlueSky Immunotherapies’s current revenue?
The current revenue for BlueSky Immunotherapies is .
-
How much funding has BlueSky Immunotherapies raised over time?
BlueSky Immunotherapies has raised $2.05M.
-
Who are BlueSky Immunotherapies’s investors?
Forschungsförderungsgesellschaft, INiTS Universitäres Gründerservice, The Austrian Research Promotion Agency, and Vienna Business Agency have invested in BlueSky Immunotherapies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
